According to a recent study, in heart failure with reduced ejection fraction (HFrEF) patients, elevated high-sensitivity ...

The year saw the emergence of a new version of an old drug that proved beneficial in patients who have heart failure with ...

The FDA has followed the advice of its expert advisors and rejected Cytokinetics’ cardiac myosin activator omecamtiv mecarbil as a treatment for heart failure, saying the efficacy data for the drug ...

Bayer's mineralocorticoid receptor antagonist (MRA) Kerendia hit the mark as a treatment for a common form of heart failure in the FINEARTS-HF study, setting up regulatory approvals, but there is some ...

Background Multiple long-term conditions (MLTCs) are common among individuals with heart failure (HF); however, the influence ...

CLOSURE-AF and CREST-2 were widely read, but stories on GLP-1s, DOACs in AF, and a new PCSK9 inhibitor were popular, too.